Théophile Godfraind - Curriculum vitae#

Education

  • 1958 Diplome Institut de Médecine Tropicale, Anvers, Belgium
  • 1958 Agrégé de 'Enseignement Superieur en Medecine Université Catholique de Louvain, Belgium
  • 1955 Docteur en Medecine (Summa cum Laude) Université Catholique de Louvain, Belgium
  • 1951 Candidat (Grande Distinction) Université Libre de Bruxelles, Belgium

Appointments/Affiliations
  • 2001-Present President and Founding Father, Belgian College of Pharmaceutical Medicine, Brussels, Belgium
  • 2000, 2001 Invited Professor, University of Bratislava, Slovakia
  • 1999 Invited Professor, University of Rio de Janeiro, Brazil
  • 1996-Present Professor Emeritus, Universite Catholique de Louvain, Brussels, Belgium
  • 1996-Present Coordinator of Research in Experimental Pharmacology, Comenius University, Bratislava, Slovakia
  • 1996, 1997, 1998, 1999 Invited Professor, University of Bratislava, Slovakia
  • 1994-1998 President, International Union of Pharmacology, Irvine, CA, United States
  • 1992-1996 Chairperson Academia Europaea, Subject Group Pharmacology & Toxicology, London, UK
  • 1990, 1991, 1992 Invited Professor, University of Nancy, France
  • 1987-1994 Secretary General, International Union of Pharmacology, Irvine, CA, United States
  • 1987 Invited Professor, University of Cambridge, UK
  • 1985-1986 Temporary Advisor World Health Organization, Geneva, Switzerland
  • 1983-1994 President, Centre d'Etudes Bioethiques de Bruxelles, Belgium
  • 1980 Invited Professor, University of Kiel, Germany
  • 1978, 1979 Invited Professor, University of Toulouse, France
  • 1976-Present Member of the Medical Ethical Committee, Fonds National de la Recherche, Brussels, Belgium
  • 1974 Invited Professor, University of Antwerp, Belgium
  • 1974 Invited Professor, Louis Pasteur Strasbourg, France
  • 1974 Invited Professor, University of Zurich, Switzerland
  • 1973, 1974, 1977, 1979 Invited Professor, Univeristy of Paris-Sud, France
  • 1973 Invited Professor, Univeristy of Nijmegen, Netherlands
  • 1971-Present, Secretary General, Belgian Society of Clinical and Experimental Physiology and Pharmacology, Leuven, Belgium
  • 1966-Present Director of Research in Experimental Pharmacology, Universite Catholique de Louvain, Faculty of Medicine, Leuven, Belgium
  • 1966-1996 Ordinary Professor, Universite Catholique de Louvain, Faculty of Medicine, Brussels, Belgium
  • 1964-1966, Professor, Universite Catholique de Louvain, Faculty of Medicine, Brussels, Belgium
  • 1964- 1996 Director, Universite Catholique de Louvain, Faculty of Medicine, Laboratoryof Pharmacology, Brussels, Belgium
  • 1964, 1970, 1973 Invited Professor, University of Paris, Faculties of Medicine and Pharmacy, Paris, France
  • 1958-1964 Professor of Pharmacology, University Lovanium, Kinshasa, Zaire Dem Rep Congo

Memberships
  • 2000-Present Acta Phanrmacologica Sinica, Member, Editorial Board
  • 1998-Present International Union of Pharmacology, Past President
  • 1997 Academie Nationale de Medecine de France, Associate Member
  • 1996-Present Journal of Cardiovascular Pharmacology, Member, Editorial Board
  • 1993-Present Cardiovascular Drugs and Therapy, Member, Editorial Board
  • 1993-Present Comptes Rendus des Seances de la Societe de Biologie et de SesFiliales, Member, Editorial Board
  • 1992-Present Pharmacology Reviews and Communications, Member, Editorial Board
  • 1992-1996 Academia Europaea, Subject Group of Pharmacology & Toxicology, Chairperson
  • 1991 Academie Royale de Medicine de Belgique, President
  • 1990-Present Therapie, Member, Editorial Board
  • 1990 Academia Europaea, Member
  • 1989-Present Annales Pharmaceutiques Francaises, Member, Editorial Board
  • 1989-1998 Cardiovascular Drug Reviews Member, Editorial Board
  • 1988-Present Pharmacological Research Communications, Member, Editorial Board
  • 1988-1990 Academie Royale de Medecine de Belgique, Vice-President
  • 1988-1989 Research Reviews in Pharmacology, Member, Editorial Board
  • 1988 Academie Nationale de Medecine de France, Foreign Corresponding Member
  • 1987-Present Pharmacology and Toxicology, Member, Editorial Board
  • 1987-1990 Fundamental and Clinical Pharmaocology, Member, Editorial Board
  • 1985-Present International Union of Therapeutics, Member, Executive Committee
  • 1984 Academie Royale de Medecine de Belgique, Regular Member
  • 1983-Present Journal de Pharmacie de Belgique, Member, Editorial Board
  • 1981-1998 British Journal of Pharmacology, Member, Editorial Board
  • 1980 Academie Nationale de Pharmacie de France, Corresponding Member
  • 1979-Present Trends in Pharmacological Sciences, Member, Editorial Board
  • 1974-Present Biochemical Pharmacology Member, Editorial Board
  • 1974 Academie Royale de Medecine de Belgique, Corresponding Member
  • 1972-1984 Bulletin Signaletique du C.N.R.S., Member, Editorial Board
  • 1970-1980 Archives Internationales de Physiologie et de Biochimie, Member, Editorial Board
  • 1969-1978 European Journal of Pharmaoclogy, Member, Editorial Board
  • 1964-1990 Archives Internationales de Pharmacodynamie et de Therapie, Member, Editorial Board
  • Societe Belge de Physiologie et de Pharmacologie Fondamentalesat Cliniques, Member
  • Societe Francaise de Pharmacologie, Member
  • Societe de Physiologie, Member
  • Deutsche Pharmakologische Gezellschaft, Member
  • Biochemical Society, Member
  • British Pharmacological Society, Member
  • Physiological Society, Member
  • New York Academy of Sciences, Member
  • American Society for Pharmacology and Experimental Therapeutics, Member
  • International Society for Heart Research, Member
  • American Journal of Physiology, Referee
  • Circulation Research, Referee
  • European Journal of Physiology, Referee
  • Journal of Hypertension, Referee
  • Hypertension, Referee

Research Interests

The main area of research interest concerns the mode of action of agents (including neurotransmitters and xenobiotics) interacting withvoltage-operated calcium channels. The problem is to understand how calcium channel blockade is translated into therapeutic action in various cardiovascularand neurological diseases.

Current interest centers on the genomic action and the tissue selectivity of calcium channel blockers with special emphasis on their effects on changesin receptor-response coupling, on tissue remodelling and the expression of related genes observed in diseases of the cardiovascular system, such as hypertension, stroke and atherosclerosis.
Imprint Privacy policy « This page (revision-2) was last updated on Wednesday, 23. November 2016, 10:41 by Kaiser Dana
  • operated by